The Use Of Continuous Chromatography In Effective Process Design To Be Presented By 探花合集 Biologics Expert At PREP Symposium
SOMERSET, N.J. 鈥 July 2, 2019听鈥 探花合集, the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Ben Kester, Manager and Senior Scientist, Purification Development, 探花合集 Biologics, will present at the upcoming 32nd听International Symposium on Preparative and Process Chromatography (PREP Symposium) at the Hyatt Regency Baltimore Inner Harbor, Baltimore, Maryland on July 7 鈥 10, 2019.
On Monday, July 8 at 4:20 p.m., Mr. Kester will present 鈥Strategies for Process Design: Unlocking Combinations with Continuous Chromatography and Cutting-Edge Technologies鈥. The session will explore the latest technologies available when designing a process, with a focus on continuous chromatography, highlighting how the technique can provide a range of adjustability to improve timelines and efficiency. Mr. Kester will include case studies in the presentations to demonstrate the technology鈥檚 use with a number of products with different challenges, such as stability issues.
In his role at 探花合集, Mr. Kester is responsible for downstream purification development at the 探花合集 Biologics facility in Bloomington, Indiana. He oversees process design and characterization and facilitates technical transfer to cGMP production. He has a bachelor鈥檚 degree in cellular and molecular biology from Grand Valley State University, Allendale, Michigan and a master鈥檚 degree in biochemistry from Indiana University Bloomington.
To arrange a meeting with Mr. Kester at the event, contact Richard Kerns at NEPR –听[email protected].
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns, NEPR
+44 (0)161 728 5880
[email protected]
ABOUT CATALENT BIOLOGICS
探花合集 Biologics has 20+ years鈥 experience in development, manufacturing, and analytical services for new biological entities, biosimilars, and antibody-drug conjugates. 探花合集 has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials and 11 marketed products have used GPEx庐听cell line engineering technology. A further 20 commercially-approved products have employed 探花合集 Biologics鈥 capabilities through to aseptic fill/finish. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, 探花合集 Biologics brings better biologic treatments to patients, faster. For more information, visit听听
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.